Disease Areas
Diabetes
Obesity
Cardiovascular Disease (CVD)
Chronic Kidney Disease (CKD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Neurodegenerative Diseases
Haemophilia
Sickle Cell Disease
Primary Hyperoxaluria
Growth Hormone Disorders
Hormone Replacement Therapy
Congresses
Scientific Publications
IME
Register
Login
My Account
Welcome to Novo Nordisk Science Hub
Are you a healthcare professional?
No
Yes
Congresses
31st European Congress on Obesity
STEP 10 trial: semaglutide 2.4 mg provided a superior reduction vs placebo in body weight and reversion to normoglycaemia in participants with obesity and prediabetes
31st European Congress on Obesity